The T cell-dependent bispecific (TDB) antibody, anti-CD79b/CD3, targets CD79b and CD3
cell-surface receptors expressed on B cells and T cells, respectively. Since the anti-CD79b …

CD20 is a cell‐surface receptor expressed by healthy and neoplastic B cells and is a well‐
established target for biologics used to treat B‐cell malignancies. Pharmacokinetic (PK) and …

Bispecific antibodies and antibody fragments in various formats have been explored as a
means to recruit cytolytic T cells to kill tumor cells. Encouraging clinical data have been …

Introduction: CD20-TCB (RG6026) is a novel T-cell-engaging bispecific (TCB) antibody with
a '2: 1 'molecular format that comprises two fragment antigen binding regions that bind CD20 …

Introduction: CD20-TCB (RG6026) is a novel T-cell-engaging bispecific (TCB) antibody with
a '2: 1 'molecular format that comprises two fragment antigen binding regions that bind CD20 …

Immunotherapies targeting B-lineage-specific surface marker CD19 had demonstrated
promising clinical results. Two CD19 CAR-T therapies (Kymriah® and Yescarta®) have …

Despite the recent advancements in treatment options with the introduction of anti-CD20
monoclonal antibody therapy, approximately 50% of patients with non-Hodgkin's …

High rates of relapse and poor prognosis confer an urgent need for novel therapeutic agents
for B cell non-Hodgkin lymphomas (B-NHLs). Herein, we describe a human IgG-like anti …

Despite the widespread use of rituximab, a chimeric monoclonal antibody with demonstrated
efficacy in the treatment of non-Hodgkin's lymphomas, there is a recognized need to develop …

CD47, an ubiquitously expressed innate immune checkpoint receptor that serves as a
universal “don't eat me” signal of phagocytosis, is often upregulated by hematologic and …